AstraZeneca Targets $80bn Sales By 2030 But Analysts Still To Be Convinced
The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.
The UK company has unveiled a new strategy for 2030 and beyond but analysts' forecasts fall around $15bn short of the company’s own projections.